Literature DB >> 19921311

Primary cardiac lymphoma: diagnostic tools and treatment challenges.

R Bambury1, F Gallagher, J D Dodd, D Fennelly.   

Abstract

Primary cardiac lymphoma (PCL) is a rare malignancy and the optimal treatment strategy remains uncertain. It appears to respond much better to systemic chemotherapy than to surgery and it should be considered in the differential diagnosis of all cardiac tumours before definitive management is undertaken. We report a case of this rare disorder treated successfully with a combination of rituximab and cyclophosphamide, adriamycin, vincristine and prednisolone. The patient developed recurrent unstable ventricular tachycardia (VT) post-chemotherapy secondary to extensive scarring at the tumour site. The tumour as well as the post-treatment scarring is well illustrated by cardiac magnetic resonance imaging highlighting its usefulness in this setting. An implantable cardioverter defibrillator (ICD) was placed. This is only the second case in the literature of PCL to have an ICD placed for recurrent VT. A brief literature review is included.

Entities:  

Mesh:

Year:  2009        PMID: 19921311     DOI: 10.1007/s11845-009-0446-x

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  5 in total

1.  [Therapy-resistant ventricular tachycardia in a woman with primary cardiac non-Hodgkin lymphoma].

Authors:  O Kohl; H Hölschermann; H Pralle; H von Lieven; R M Bohle; J Thormann; B Waldecker
Journal:  Med Klin (Munich)       Date:  2000-09-15

Review 2.  Primary lymphoma of the heart. A case report and review of the literature.

Authors:  Giovanni Rolla; Maria Tiziana Bertero; Guglielmo Pastena; Nicoletta Tartaglia; Federica Corradi; Riccardo Casabona; Manuela Motta; Federico Caligaris-Cappio
Journal:  Leuk Res       Date:  2002-01       Impact factor: 3.156

3.  A case of primary cardiac B cell lymphoma associated with ventricular tachycardia, successfully treated with systemic chemotherapy and radiotherapy: a long-term survival case.

Authors:  T Miyashita; I Miyazawa; T Kawaguchi; T Kasai; T Yamaura; T Ito; M Takei; K Kiyosawa
Journal:  Jpn Circ J       Date:  2000-02

Review 4.  Primary cardiac lymphoma in immunocompetent patients: a report of three cases and review of the literature.

Authors:  Lara Chalabreysse; Françoise Berger; Robert Loire; Gilles Devouassoux; Jean-François Cordier; Françoise Thivolet-Bejui
Journal:  Virchows Arch       Date:  2002-09-27       Impact factor: 4.064

5.  Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance.

Authors:  James C C Moon; William J McKenna; Jane A McCrohon; Perry M Elliott; Gillian C Smith; Dudley J Pennell
Journal:  J Am Coll Cardiol       Date:  2003-05-07       Impact factor: 24.094

  5 in total
  5 in total

1.  Investigation of cardiomyopathy using cardiac magnetic resonance imaging part 1: Common phenotypes.

Authors:  Shaunagh McDermott; Ailbhe C O'Neill; Carole A Ridge; Jonathan D Dodd
Journal:  World J Cardiol       Date:  2012-04-26

Review 2.  Evaluation and Management of Cardiac Tumors.

Authors:  Nicolas Palaskas; Kara Thompson; Gregory Gladish; Ali M Agha; Saamir Hassan; Cezar Iliescu; Peter Kim; Jean B Durand; Juan C Lopez-Mattei
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-20

3.  Diffuse infiltrative primary cardiac lymphoma with delayed extracardiac involvement.

Authors:  Yong Jeoung; Se Ryeon Lee; Ho Kim; Ji Won Kim; Jae Joong Lee; Sang Yoon Chung
Journal:  Chonnam Med J       Date:  2014-04-22

4.  Primary Cardiac Lymphoma: Lessons Learned from a Long Survivor.

Authors:  Baljit Singh; Randy Ip; Ahmed Ibrahim Al-Rajjal; Zyad Kafri; Ayad Al-Katib; Tarik Hadid
Journal:  Case Rep Cardiol       Date:  2016-12-07

5.  Primary cardiac lymphoma (PCL) - diagnostic difficulties.

Authors:  Karolina Skalec; Linda Litwin; Katarzyna Drozdz; Pawel Gac; Przemyslaw Jazwiec; Mariusz Chabowski; Robert Zymlinski; Wlodzimierz Molenda; Andrzej Szuba; Dariusz Janczak
Journal:  Kardiochir Torakochirurgia Pol       Date:  2015-09-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.